Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nacubactam
- Development stage
- Phase 3
- Lead developer
- Meiji Seika Pharma
- Modality
- Classical Binding Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Nacubactam is a novel small molecule beta-lactamase inhibitor developed to combat bacterial resistance to beta-lactam antibiotics. It acts through dual mechanisms of action: (1) inhibition of serine beta-lactamases (classes A and C and some class D), thereby protecting coadministered beta-lactams from enzymatic degradation; and (2) direct inhibition of penicillin binding protein 2 (PBP2) in Enterobacteriaceae, which impairs bacterial cell wall synthesis. Nacubactam is primarily being developed for use in combination with the carbapenem antibiotic meropenem for the treatment of serious gram-negative infections such as complicated urinary tract infections and pyelonephritis. The drug has demonstrated safety and tolerability in phase I studies and has advanced to phase III clinical trials[3][6][7].
- Other names
- nacubactam
02
Targets
NeuraminidasePBP2 (Penicillin-binding protein 2)
Beyond the preview
Go deeper on Nacubactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nacubactam.